news-med.jpg

Evotec and Bayer Advance Third Endometriosis Programme into Phase I Clinical Development

Hamburg, Germany, 18 April 2018: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its multi-target alliance with Bayer has advanced another promising small molecule into Phase I for the treatment of endometriosis, a painful, debilitating reproductive ...

Topics: Corporate, Bayer, Endometriosis, Phase I Read More

Evotec forms collaboration with Petra Pharma on INDiGO platform

Petra Pharma Corporation to harness Evotec's INDiGO platform to accelerate its lead programme (Petra-01 for oncology indications) through IND filing Evotec eligible to receive success-based milestones and research funding Evotec's INDiGO, a key value-driving component of its EVT Execute business ...

Topics: Corporate, INDiGO Read More

Evotec launches INDiGO®, a unique integrated drug development solution for accelerating early drug candidates into the clinic

INDiGO® is the market leading integrated drug development solution that accelerates drug candidate delivery from candidate selection through to IND submission in typically less than 52 weeks.

Topics: Corporate, INDiGO Read More

Evotec and Apeiron Achieve First Milestone in Immuno-Oncology Alliance with Sanofi

Hamburg, Germany and Vienna, Austria, 08 January 2018: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and APEIRON Biologics AG, a company focused on cancer immunotherapy, announced today that the companies received the first milestone payment from Sanofi under a 3 party ...

Topics: Corporate, Apeiron, Sanofi, pre-clinical development, immuno-oncology Read More

Evotec Enters into Research Collaboration with CRTD to Discover Novel Therapies for Retinal Diseases

COLLABORATION HIGHLIGHTS EVT INNOVATE’S BUSINESS MODEL TO ACCESS LEADING ACADEMIC EXPERTISE CRTD’S NEXT GENERATION STEM CELL MODELLING WILL ACCELERATE EVOTEC’S ABILITY TO DISCOVER NEW RETINAL DISEASE DRUGS Dresden and Hamburg, Germany, 13 December 2017: Evotec AG (Frankfurt Stock Exchange: EVT, ...

Topics: Corporate, Research collaboration, Retinal diseases Read More

Evotec’s Academic Bridge LAB282 with Oxford University Celebrating One Year of Impact

THE £ 13 M DRUG DISCOVERY PARTNERSHIP BETWEEN OXFORD UNIVERSITY, OXFORD SCIENCES INNOVATION AND EVOTEC SUPPORTED 12 NEW PROJECTS IN FIRST YEAR OF OPERATION Hamburg, Germany, 11 December 2017: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that LAB282, the £ 13 ...

Topics: Corporate, Drug Discovery Read More

Evotec Receives Clinical Milestone as Part of its Discovery Alliance with Boehringer Ingelheim

ACHIEVEMENT MARKS 24TH MILESTONE UNDER ALLIANCE TO DATE Hamburg, Germany, 01 December 2017: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that it has achieved a clinical milestone under its drug discovery alliance with Boehringer Ingelheim triggering revenues ...

Topics: Corporate, Business, Drug Discovery, Contract Reseach Organization, Respiratory Read More

Evotec AG announces first nine-month 2017 results and corporate update

Strong operational and financial performance Expansion of leading external innovation platform through acquisition of aptuit Important milestone achievements and new ways of accelerating innovation Hamburg, Germany, 08 November 2017: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: ...

Topics: Corporate, Drug Development, Drug Discovery Read More

Evotec joins forces with Academic Leaders to accelerate Drug Discovery in kidney diseases and build “Neplex”

Collaboration aimed at developing novel “Nephron-on-a Chip” device to test drug candidates in human kidney: NEPLEX (“Nephron-on-a-Chip with Cellular and Extracellular Matrix Complexity”) Major step forward to the next generation Kidney Platform Hamburg, Germany, 06 November 2017: Evotec AG ...

Topics: Corporate, Drug Development, Drug Discovery Read More

Evotec AG to report first nine-month 2017 results on 08 November 2017

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) will report its financial results for the first nine months of 2017 on Wednesday, 08 November 2017. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The ...

Topics: Corporate Read More